SmithKline Beecham and Takeda Chemical Industries are considering a collaboration in the area of combinatorial chemistry. Under the terms of the proposed agreement, the two companies would share their existing combinatorial chemistry technologies, which includes exchanging libraries for use in their internal drug screening programs, and developing novel approaches.
SB and Takeda have an existing collaboration in genomics, and George Poste, chairman of R&D at SB Pharmaceuticals, said that the success of this earlier venture prompted the new deal. As part of the new collaboration, both SB and Takeda will have access to the high-throughput combinatorial chemistry system under development by Orchid Biocomputer Inc, which was formed in September 1995 by the David Sarnoff Research Centre in collaboration with SB.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze